Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

3(33.3%)

Early Phase 1

3(33.3%)

Phase 3

2(22.2%)

Phase 2

1(11.1%)

9Total

Phase 1(3)

Early Phase 1(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07053358Early Phase 1Recruiting

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Role: collaborator

NCT07362927Early Phase 1Recruiting

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Role: collaborator

NCT07063030Early Phase 1Recruiting

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

Role: collaborator

NCT06196827Phase 1Active Not Recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Role: lead

NCT06196840Phase 2Active Not Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Role: lead

NCT07317934Phase 3Recruiting

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Role: lead

NCT07054632Phase 3Active Not Recruiting

Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Role: lead

NCT06198413Phase 1Active Not Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Role: lead

NCT06212297Phase 1Active Not Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Role: lead

All 9 trials loaded